Literature DB >> 12969555

New HLA-A, -B, and -C locus-specific primers for PCR amplification from cDNA: application in clinical immunology.

Maria P Bettinotti1, Lejla Hadzikadic, Erin Ruppe, Gitika Dhillon, David S Stroncek, Francesco M Marincola.   

Abstract

The individual cellular immune response to intracellular antigens is modeled by the highly polymorphic major histocompatibility complex (HLA) class I molecules. The epitopes presented and the T cell repertoire that recognizes them depend on the HLA constitution of the individual. Therefore, to monitor and to modify an individual's HLA class I-driven cellular immune response, it is necessary to know the HLA class I alleles of the person and the possible epitopes of the target antigen presented by those alleles. In particular, this is necessary in order to design peptide-based vaccines and immune therapies for the treatment of diseases caused by viruses, intracellular parasites or cancer, and to monitor the immune response during those treatments. We describe a new set of HLA-A, -B, and -C locus-specific primers for the polymerase chain reaction (PCR) amplification of the whole coding sequence of these genes from complementary DNA (cDNA). We describe their use for typing and for the production of a library of recombinant HLA class I genes. We discuss two downstream applications of this gene collection: production of soluble HLA molecules and discovery of new epitopes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969555     DOI: 10.1016/s0022-1759(03)00233-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Unbiased identification of target antigens of CD8+ T cells with combinatorial libraries coding for short peptides.

Authors:  Katherina Siewert; Joachim Malotka; Naoto Kawakami; Hartmut Wekerle; Reinhard Hohlfeld; Klaus Dornmair
Journal:  Nat Med       Date:  2012-05       Impact factor: 53.440

2.  Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.

Authors:  Jianping Huang; Hung T Khong; Mark E Dudley; Mona El-Gamil; Yong F Li; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2005 May-Jun       Impact factor: 4.456

3.  Restoration of Immune Privilege in Human Dermal Papillae Controlling Epithelial-Mesenchymal Interactions in Hair Formation.

Authors:  Jung Min Park; Mee Sook Jun; Jung-A Kim; Nanda Maya Mali; Tsai-Ching Hsi; Areum Cho; Jung Chul Kim; Jun Young Kim; Incheol Seo; Jungmin Kim; Moonkyu Kim; Ji Won Oh
Journal:  Tissue Eng Regen Med       Date:  2021-10-09       Impact factor: 4.451

4.  Polymorphisms and tissue expression of the feline leukocyte antigen class I loci FLAI-E, FLAI-H, and FLAI-K.

Authors:  Jennifer C Holmes; Savannah G Holmer; Peter Ross; Adam S Buntzman; Jeffrey A Frelinger; Paul R Hess
Journal:  Immunogenetics       Date:  2013-06-30       Impact factor: 2.846

5.  T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product.

Authors:  Jianping Huang; Mona El-Gamil; Mark E Dudley; Yong F Li; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

6.  Towards the simplification of MHC typing protocols: targeting classical MHC class II genes in a passerine, the pied flycatcher Ficedula hypoleuca.

Authors:  David Canal; Miguel Alcaide; Jarl A Anmarkrud; Jaime Potti
Journal:  BMC Res Notes       Date:  2010-09-05

7.  Sampling strategies for accurate computational inferences of gametic phase across highly polymorphic major histocompatibility complex loci.

Authors:  Miguel Alcaide; Airam Rodríguez; Juan J Negro
Journal:  BMC Res Notes       Date:  2011-05-26

8.  Unique Molecular Identifier-Based High-Resolution HLA Typing and Transcript Quantitation Using Long-Read Sequencing.

Authors:  Caleb Cornaby; Maureen C Montgomery; Chang Liu; Eric T Weimer
Journal:  Front Genet       Date:  2022-06-13       Impact factor: 4.772

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.